$990,000 of BIOGEN lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income. Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill. Trade-related public policy around tariffs and intellectual property, no related bills"
You can find more data on corporate lobbying on Quiver Quantitative.
BIIB Congressional Stock Trading
Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN purchased up to $15,000 on 05/15.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BIIB Insider Trading Activity
BIIB insiders have traded $BIIB stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 4,323 shares for an estimated $549,552.
- RACHID IZZAR (Head of Global Product Strat.) sold 2,223 shares for an estimated $300,105
- CAROLINE DORSA purchased 1,235 shares for an estimated $151,559
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIIB Hedge Fund Activity
We have seen 418 institutional investors add shares of BIIB stock to their portfolio, and 360 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 3,424,470 shares (+840.9%) to their portfolio in Q2 2025, for an estimated $430,079,187
- BLACKROCK, INC. removed 1,655,570 shares (-10.9%) from their portfolio in Q2 2025, for an estimated $207,923,036
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,265,814 shares (-47.6%) from their portfolio in Q2 2025, for an estimated $158,973,580
- AMUNDI removed 736,150 shares (-55.9%) from their portfolio in Q2 2025, for an estimated $92,453,078
- OVERSEA-CHINESE BANKING CORP LTD removed 734,587 shares (-94.1%) from their portfolio in Q2 2025, for an estimated $92,256,781
- SG AMERICAS SECURITIES, LLC removed 697,323 shares (-96.9%) from their portfolio in Q2 2025, for an estimated $87,576,795
- ORION PORFOLIO SOLUTIONS, LLC added 509,809 shares (+6828.4%) to their portfolio in Q2 2025, for an estimated $64,026,912
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIIB Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 09/25/2025
- RBC Capital issued a "Outperform" rating on 08/01/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/01/2025
- Mizuho issued a "Outperform" rating on 05/07/2025
- Canaccord Genuity issued a "Buy" rating on 05/02/2025
- Baird issued a "Outperform" rating on 05/02/2025
- Truist Securities issued a "Buy" rating on 04/29/2025
To track analyst ratings and price targets for BIIB, check out Quiver Quantitative's $BIIB forecast page.
BIIB Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 13 analysts offer price targets for $BIIB in the last 6 months, with a median target of $175.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $149.0 on 10/10/2025
- Andrew Tsai from Jefferies set a target price of $190.0 on 09/25/2025
- David Amsellem from Piper Sandler set a target price of $118.0 on 08/14/2025
- Geoff Meacham from Citigroup set a target price of $135.0 on 08/01/2025
- Brian Abrahams from RBC Capital set a target price of $219.0 on 08/01/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $194.0 on 08/01/2025
- Laura Chico from Wedbush set a target price of $121.0 on 06/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
